The largest database of trusted experimental protocols
> Disorders > Sign or Symptom > Upper Extremity Paresis

Upper Extremity Paresis

Upper Extremity Paresis is a condition characterized by partial or complete weaknes of the arm, forearm, or hand muscles, often resulting from neurological impairment.
It can arise from a variety of underlying causes, such as stroke, spinal cord injury, or neuromuscular disorders.
Affected individuals may experience difficulty with activities of daily living, including grasping, reaching, and manipulating objects.
Accurate assessment and optimization of research protocols are critical for developing effective interventions to improve upper extremity function and enhance the quality of life for individuals living with paresis.
PubCompare.ai offers a powerful suite of AI-driven tools to locate the best protocols from literature, pre-prints, and patents, enabling researchers to reproducibly and accurately study upper extremity paresis and advance the field of rehabilitation science.

Most cited protocols related to «Upper Extremity Paresis»

Focal transient cerebral ischemia was induced by MCAO (0.21mm silicone coated suture) for 90 minutes followed by reperfusion as described previously (McCullough et al. 2005 (link)). In aging mice a larger 0.23mm silicone coated suture was utilized to achieve occlusion. Sham animals were subjected to sutures of the same size but the suture was not advanced into the middle cerebral artery. Cerebral blood flow (CBF) was measured by laser Doppler flowmetry (LDF, Moor Instruments Ltd, England) during the surgery as previously described (McCullough et al. 2005 (link)). Only the mice in which CBF in MCA area showed a sharp drop of over 85% of control immediately after MCA occlusion were included.
Neurological deficit was confirmed and scored as follows: 0, no deficit; 1, forelimb weakness and torso turning to the ipsilateral side when held by tail; 2, circling to affected side; 3, unable to bear weight on affected side; and 4, no spontaneous locomotor activity or barrel rolling. Monitoring of physiological variables was performed in companion cohorts for all groups prior to MCAO and 60 minutes after reperfusion as described previously (McCullough et al. 2005 (link)).
In ovariectomized (Ovx) females the ovaries were surgically removed 10 days prior to MCAO as described previously (McCullough et al. 2005 (link)). In E2 treated mice 17β-estradiol was delivered by subcutaneous SILASTIC capsule (0.062 inch inner diameter; 0.125 inch outer diameter) filled with 0.035 ml of 17β-estradiol (180μg/ml; Sigma) (McCullough et al. 2005 (link)) in sesame oil implanted at the time of ovariectomy. Serum 17β-estradiol and levels of the inflammatory marker IL-6 was measured in each group by ELISA (E2: IBL HAMBURG, Hamburg, Germany; IL-6: eBioscience, San Diego, CA). Uteruses of female mice were also weighed at sacrifice to confirm end-organ estrogen effects and ELISA values.
Publication 2009
Animals ARID1A protein, human Bears Capsule Cerebrovascular Circulation Dental Occlusion Enzyme-Linked Immunosorbent Assay Estradiol Females Inflammation Laser-Doppler Flowmetry Locomotion Mus Operative Surgical Procedures Ovariectomy Ovary Pets Reperfusion Serum Sesame Oil Silastic Silicones Sutures Tail Torso Transient Cerebral Ischemia Upper Extremity Paresis Uterus

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Amputation Stumps Anesthesia Animals ARID1A protein, human Bears Blood Circulation Cerebral Ischemia Cerebrovascular Circulation Cranium External Carotid Arteries Internal Carotid Arteries Ischemia Isoflurane Locomotion Middle Cerebral Artery Mus Muscle Tissue Neck Operative Surgical Procedures Rectum Reperfusion Silicone Elastomers Sutures Tail Torso Upper Extremity Paresis

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2012
Acclimatization Cerebrovascular Accident Dupuytren Contracture Fingers Patients Upper Extremity Paresis

Adoptively-transferred EAE. It was performed as described previously by us [11 (link), 12 (link), 13 (link), 14 (link)]. Briefly, 4–5 weeks old female SJL/J mice were purchased from Harlan Sprague-Dawley (Indianapolis, IN). Donor mice were immunized s.c. with 400 µg bovine MBP and 60 µg M. tuberculosis in IFA [11 (link), 12 (link), 13 (link), 14 (link)]. Animals were killed 10–12 days postimmunization, and the draining lymph nodes were harvested and single cell suspensions were cultured in RPMI 1640 supplemented with 10% FBS, 50 µg/mL MBP, 50 µM 2-ME, 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/ml streptomycin. On day 4, cells were harvested and resuspended in HBSS. A total of 2 × 107 viable cells in a volume of 200 µL were injected into the tail vein of naive mice. Pertussis toxin (150 ng/mouse; Sigma-Aldrich) was injected once via i.p. route on 0 day post-transfer (dpt) of cells. Animals were observed daily for clinical symptoms. Six mice were used in each group. Female mice (4–5 week old) were randomly selected for any group. Experimental animals were scored by a masked investigator, as follows: 0, no clinical disease; 0.5, piloerection; 1, tail weakness; 1.5, tail paralysis; 2, hind limb weakness; 3, hind limb paralysis; 3.5, forelimb weakness; 4, forelimb paralysis; 5, moribund or death.
A mouse was considered moribund when it showed any of the following criteria. Conditions for moribund were as follows: Prolonged inappetance; Evidence of muscle atrophy; Central nervous system disturbance (Head tilt, Seizures, Tremors, Circling, Spasticity, and Paresis); Chronic diarrhea or constipation; Rough coat and distended abdomen; Spreading area of alopecia caused by disease; Coughing, rales, wheezing and nasal discharge; Distinct jaundice and/or paleness (anemia); Markedly discolored urine, polyuria or anuria; Inability to remain upright; Frank bleeding from any orifice; Persistent self-induced trauma.
Relapsing EAE in 5B6 PLP-TCR Tg mice. Female Tg mice (4–5 weeks old) were immunized with 10 or 25 µg of PLP139–151 in M. tuberculosis in IFA as described above. Mice also received pertussis toxin (150 ng/mouse) once on 0 day post-immunization (dpi). In the EAE group (Fig. 1B), where female PLP-TCR transgenic mice were immunized with 25 μg PLP139–151, two mice died without humane intervention on 17 days post-immunization (dpi) and four moribund mice were decapitated after anesthesia. However, according to the disease scale, all six mice in this group received a score of 5.
Chronic EAE. C57BL/6 mice were immunized with 100 μg of MOG35–55 as described above. Mice also received two doses of pertussis toxin (150 ng/mouse) on 0 and 2 dpi.
Publication 2015
Abdomen Alopecia Anemia Anesthesia Animals Animals, Laboratory Anuria Asthenia Bos taurus Cells Central Nervous System Constipation Diarrhea Females Glutamine Head Hemoglobin, Sickle Hindlimb Icterus Mice, Inbred C57BL Mice, Transgenic Mus Muscle Spasticity Muscular Atrophy Mycobacterium tuberculosis Nodes, Lymph Paresis Penicillins Pertussis Toxin Piloerection Polyuria Rhinorrhea Seizures Streptomycin Tail Tissue Donors Training Programs Tremor Upper Extremity Upper Extremity Paresis Urine Vaccination Veins Wounds and Injuries
The FAST-ED scale (Facial Palsy (scored 0–1), Arm Weakness (0–2), Speech Changes (0–2), Time (documentation for decision making but no points), Eye Deviation (0-2), and Denial/Neglect (0-2)) was designed based on items of the NIHSS with higher predictive value for LVOS. In addition, time was included considering its importance in the pre-hospital decision algorithm. For the current analysis, the FAST-ED score was derived from the NIHSS score assessed by certified research personnel at hospital admission and is shown in Table 110 (link).
The scale was tested on data from 741 consecutive patients enrolled in a prospective cohort study at two university-based hospitals, the Screening Technology and Outcomes Project in Stroke (STOPStroke), in which admission non-enhanced CT scans (NCCT) and computed tomography angiography (CTA) were obtained in all patients suspected of having ischemic stroke (stroke, transient ischemic attack, or stroke mimics) in the first 24 hours of symptom onset. Patients were excluded if iodinated contrast agent administration was contraindicated (i.e., history of contrast agent allergy, pregnancy, congestive heart failure, increased creatinine level) or if there was evidence of intracranial hemorrhage on NCCT. The STOPStroke study received institutional review board approval at both participating institutions and was Health Insurance Portability and Accountability Act compliant.
For the present study, patients with unilateral acute complete symptomatic occlusion of the intracranial internal carotid artery (intracranial ICA), M1 and/or M2 segments of the middle cerebral artery (MCA) and basilar artery (BA) were selected and compared with patients without a proximal intracranial occlusion. Patients with symptomatic bilateral, and/or anterior + posterior circulation occlusions were excluded from the analysis. Our pre-specified hypothesis was that the FAST-ED would have similar or higher accuracy than other pre-existing scales.
Publication 2016
3-chloro-4,4-dimethyl-2-oxazolidinone Angle Class III Basilar Artery Cerebrovascular Accident Computed Tomography Angiography Congestive Heart Failure Creatinine Denial, Psychology Dental Occlusion Ethics Committees, Research Hypersensitivity Internal Carotid Arteries Intracranial Hemorrhage Middle Cerebral Artery Paralysis, Facial Patients Pregnancy Speech Strabismus Stroke, Ischemic Transient Ischemic Attack Upper Extremity Paresis X-Ray Computed Tomography

Most recents protocols related to «Upper Extremity Paresis»

Example 3

A 20 year-old overweight male subject with poor blood circulation, excess lactic acid, weak arms, weak joint and muscle mobility, and—is positioned in a 360-degree full body light therapy device. The 360-degree light therapy device is configured as follows: (a) a first type of light emitting diode (LED) emits a wavelength of 650 nm, (b) a second type of LED emits a wavelength of 800 nm, (c) a third type of LED emits a wavelength of about 835 nm, and (d) a fourth type of LED emits a wavelength of about 1000 nm.

The light therapy device has: 11520 first LED types (about 25.6% of the total LEDs), 5760 second LED types (about 12.8% of the total LEDs), 21960 third LED types (about 48.8% of the total LEDs), and 11520 fourth LED types (about 25.6% of the total LEDs). The LEDs emit with a power density of about 80 mW/cm2. The LEDs emit power at about 50 Joules/cm2 in a time period of about 10 minutes. The light therapy device is configured to pulse at a rate of about 5 kHz with an 85% duty cycle.

The subject undergoes a 30-minute session of irradiation once per week 8 straight weeks. After the 8 weeks of treatment, the subject loses 3% of previous body weight, increases weight-lifting ability by about 10% in the arms, and increases mobility by about 5%.

Patent 2024
Aftercare Arm, Upper Blood Circulation Body Weight Debility Enzyme Multiplied Immunoassay Technique Joints Lactic Acid Light Males Medical Devices Muscle Tissue Phototherapy Pulse Rate Radiotherapy Range of Motion, Articular Upper Extremity Paresis

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
ARID1A protein, human Bears Locomotion Reperfusion Tail Torso Upper Extremity Paresis
Stroke survivors included in this research [n = 17] participated in the clinical trial E-BRAiN and completed the 2-week course of humanoid robot-led therapy. They received ten arm rehabilitation sessions (one introductory session with a human therapist and nine sessions with the humanoid robot) as either the arm basis training (ABT) for moderate-to-severe arm paresis [n = 9] or arm ability training (AAT) for mild arm paresis [n = 8] using the digital therapy system E-BRAiN with a humanoid robot as the therapeutic agent.
Stroke survivors with a residual arm and hand paresis who could move their arm well against gravity (shoulder abduction and elbow flexion strength ≥4 out of 5 strength grades) have no more than moderate paresis of their fingers (index and thumb strength ≥3 out of 5 strength grades), preserved selective movements of their fingers, and were capable of grasping small objects qualified for the category “mild arm paresis”, and hence, in AAT, those with more severe arm paresis (not fulfilling ≥1 criterion for mild arm paresis) fell into the category “moderate-to-severe arm paresis” and received ABT.
The AAT trains the sensorimotor efficiency by repetitive training. Eight tasks address different sensorimotor abilities such as aiming, steadiness, speed of finger movements, and finger and gross manual dexterity. During each therapeutic session, each of the eight tasks is repetitively practiced at the performance limit over four runs, each lasting approximately 1 min, while feedback as a summary of the knowledge of the results is provided intermittently. The trainee aims at improving her/his sensorimotor performance constantly. The ABT trains the selective movement capacity for individual joints of the arm and hand by repetitive movement attempts across the full range of passive movements in various directions for the shoulder, elbow, forearm, wrist, and fingers, addressed individually in a sequential way and physically assisted as needed. The graded exercises start with a single degree of freedom of the movements for all segments of the affected limb; each movement (selective active movement across the full range of a passive movement) is performed repetitively each day with assistance (e.g., weight support and completion of a movement) by a healthy subject (in the conventional setting a trained therapist) as needed (Platz, 2004 (link); Platz et al., 2009 (link)).
During the first introductory session, the participants learnt how to perform the standardised training (AAT or ABT), while the human therapist in addition noted and decided on the individualisations indicated that were then used as prescriptions for the digital therapy system E-BRAiN.
During the nine consecutive sessions, the therapeutic training was led by the humanoid robot (“robot”) providing therapeutic interaction as implemented in the digital system based on both training standards and individualisation algorithms. For safety reasons and to step in if needed, all humanoid robot-led sessions were accompanied by a supervising staff (“therapist”). The participants with moderate-to-severe arm paresis receiving the arm basis training could not necessarily perform all training movements by themselves and could perform them only to a variable degree, e.g., only with a limb weight support or over a limited range. Since the robot could not provide physical assistance and served as a social agent only (therapeutic interaction), these participants received physical assistance as needed provided by a “helper.” The helper was not a trained therapist, but was also using the instructions provided by the robot. In this research, the helper was a non-therapeutic staff member (e.g., a person with administrative or scientific duties).
Publication 2023
Brain Cerebrovascular Accident Conditioning, Psychology Forearm Gravity Healthy Volunteers Homo sapiens Joints Joints, Elbow Movement Paresis Passive Range of Motion Physical Examination Prescriptions Rehabilitation Safety Shoulder Survivors Therapeutics Thumb Upper Extremity Paresis Wrist
The participants for this study could be stroke survivors who participated in the clinical trial E-BRAiN (Evidence-based Robot Assistant in Neurorehabilitation; https://clinicaltrials.gov/ct2/show/NCT05152433) and completed the 2-week course of the humanoid robot-led therapy at one of the two study centres, i.e., the Universitätsmedizin Greifswald or the BDH-Klinik Greifswald. The eligibility criteria for the E-BRAiN trial were as follows: age ≥18 years, history of stroke (ischaemic stroke, non-traumatic intracerebral haemorrhage, and subarachnoidal haemorrhage), either stroke-related upper extremity paresis or visual neglect, not pregnant or breastfeeding, not living in custody, and providing informed consent.
The research was approved by the institution’s review board (Ethikkommission der Universitätsmedizin Greifswald; date of approval: 10.05.2021).
Publication 2023
Brain Cerebrovascular Accident Eligibility Determination Ethics Committees, Research Hemorrhage Neurological Rehabilitation Stroke, Ischemic Subarachnoid Space Survivors Therapeutics Traumatic Cerebral Hemorrhage Upper Extremity Paresis
The robot-led training sessions had audio-visually been video recorded twice, both on the first and the last (9th) session. Hence, for each participant, data of the two sessions were available for offline rating of the therapeutic interactions. The videorecorder was placed to cover the therapy scenario, its agents, the interface used for visual displays (tablet or monitor), and to show the training activity currently performed. Since the therapeutic interaction implemented in the system is either verbal or audio-visual accompanied by verbal phrases, the audio-recording was also mandatory and used for the analysis of therapeutic interactions.
The scenarios, as video recorded, differed for the following two types of trainings (compare Figure 1):

A. AAT: for stroke patients with mild arm paresis, the scenario with a patient, humanoid robot, and supervising staff (three interactive agents).

B. ABT: for patients with moderate-to-severe arm paresis, the scenario with a patient, humanoid robot, helper, and supervising staff (four interactive agents).

Even though the robot is programmed to provide all therapeutic interactions necessary, there might be situations where the therapist or the helper steps in naturally and spontaneously (they are not given instructions to do so) and provides additional therapeutic interactions.
Therefore, any therapeutic interaction as performed either by a robot, therapist, or helper was documented.
The two trained raters (Ann Louise Pedersen and Philipp Deutsch) independently analysed and documented the therapeutic interactions observed in the two video-recorded sessions per participant using the instrument THER-I-ACT and its manual. THER-I-ACT measures both the occurrence/frequency and the timing of the therapeutic interactions in the thematic fields of “information provision,” “feedback,” and “bonding” with a variety of pre-defined categories in each thematic field and in addition provides a global rating of the focussed attention and engagement for both the patient and therapist (for details, see Platz et al., 2021 (link)).
Publication 2023
Attention Cerebrovascular Accident Patients Tablet Therapeutics Training Activities Training Programs Upper Extremity Paresis

Top products related to «Upper Extremity Paresis»

Sourced in United States, Canada, United Kingdom
Pertussis toxin is a protein produced by the bacterium Bordetella pertussis, the causative agent of whooping cough. It is a key virulence factor and plays a crucial role in the pathogenesis of the disease. The toxin has multiple enzymatic activities and can modulate various cellular processes.
Sourced in United States, Germany, United Kingdom, Sao Tome and Principe, Italy, Japan, Poland, Denmark
Pertussis toxin is a bacterial protein produced by the Bordetella pertussis bacterium. It is used in laboratory settings for research purposes.
Sourced in United States, Germany, Canada, China, United Kingdom
Mycobacterium tuberculosis H37Ra is a non-virulent strain of the Mycobacterium tuberculosis bacteria. It is commonly used in research and laboratory settings as a model organism for studying the characteristics and behavior of the Mycobacterium tuberculosis species.
Sourced in United States, Germany, United Kingdom, Sao Tome and Principe, China, Macao, Italy, France, Switzerland, Canada
The CFA is a laboratory equipment that performs chemical analyses. It is designed to automate and streamline the process of analyzing chemical samples. The CFA can perform a variety of tests and measurements, such as concentration determination, pH analysis, and spectrophotometric analyses. The device is intended for use in research, industrial, and clinical laboratory settings.
Sourced in United States, China, Germany, United Kingdom, India, France, Japan, Poland, Sao Tome and Principe, Australia, Macao, Canada, Spain, Denmark, Israel, Sweden
Complete Freund's adjuvant is a laboratory reagent used to enhance the immune response in laboratory animals during the production of antibodies. It contains inactivated and dried mycobacteria suspended in a mineral oil emulsion. The mycobacteria component serves to stimulate the animal's immune system, leading to a stronger and more sustained antibody response to the antigen of interest.
Sourced in United States, Japan
MOG35–55 peptide is a laboratory reagent used in research applications. It is a synthetic peptide derived from the myelin oligodendrocyte glycoprotein (MOG) protein, which plays a role in the structure and function of the central nervous system. The MOG35–55 peptide is commonly used in experimental models to study autoimmune conditions and immunological processes.
Sourced in United States, China
Mycobacterium tuberculosis is a slow-growing, acid-fast bacillus that is the causative agent of tuberculosis. It is a critical component in the diagnosis and research of this serious infectious disease.
Sourced in United States, Japan
Incomplete Freund's adjuvant is a laboratory reagent used to enhance the immune response in animal studies. It consists of mineral oil and an emulsifier, but does not contain the killed mycobacteria that are present in Complete Freund's Adjuvant. Incomplete Freund's adjuvant is used to boost the immune response to antigens without the potential for granuloma formation.
Sourced in United States
Pertussis toxin (PTX) is a protein secreted by the bacterium Bordetella pertussis, the causative agent of whooping cough. PTX is known to possess various biological activities and is a key component in the study of signal transduction pathways.
Sourced in United States
MOG35–55 peptide is a laboratory reagent used in research applications. It is a synthetic peptide composed of amino acid residues 35 to 55 of the myelin oligodendrocyte glycoprotein (MOG) protein. This peptide is commonly used in experimental studies related to multiple sclerosis and autoimmune disorders.

More about "Upper Extremity Paresis"

Upper Extremity Paresis: Navigating the Challenges of Partial or Complete Arm, Forearm, and Hand Weakness Upper extremity paresis, a condition characterized by partial or complete weakness of the arm, forearm, or hand muscles, is often the result of neurological impairment.
This condition can arise from a variety of underlying causes, such as stroke, spinal cord injury, or neuromuscular disorders like Guillain-Barré syndrome, multiple sclerosis, or amyotrophic lateral sclerosis (ALS).
Individuals living with upper extremity paresis may experience significant difficulties with activities of daily living, including grasping, reaching, and manipulating objects.
This can have a profound impact on their quality of life and independence.
Accurate assessment and optimization of research protocols are critical for developing effective interventions to improve upper extremity function and enhance the quality of life for these individuals.
PubCompare.ai offers a powerful suite of AI-driven tools to locate the best protocols from literature, pre-prints, and patents, enabling researchers to reproducibly and accurately study upper extremity paresis and advance the field of rehabilitation science.
These tools can be particularly useful for exploring the impact of adjuvants like Pertussis toxin (PTX), Mycobacterium tuberculosis H37Ra, CFA (Complete Freund's adjuvant), and Incomplete Freund's adjuvant on the development and progression of upper extremity paresis, as well as the potential therapeutic effects of the MOG35–55 peptide.
By utilizing PubCompare.ai's advanced analytics and protocol optimization capabilities, researchers can improve their research outcomes, ultimately leading to more effective interventions and better quality of life for individuals living with upper extremity paresis.
OtherTerms: arm weakness, forearm weakness, hand weakness, neurological impairment, stroke, spinal cord injury, neuromuscular disorders, Guillain-Barré syndrome, multiple sclerosis, amyotrophic lateral sclerosis, ALS, activities of daily living, grasping, reaching, manipulating objects, Pertussis toxin, Mycobacterium tuberculosis H37Ra, CFA, Complete Freund's adjuvant, MOG35–55 peptide, Incomplete Freund's adjuvant